Shiloh
Editor, Senior Moderator
Source: https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1.full.pdf
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer1, Frances Ayres1, Tandile Hermanus1, Mashudu Madzivhandila1, Prudence Kgagudi1, Bronwen E. Lambson1,2, Marion Vermeulen3, Karin van denBerg3,4, Theresa Rossouw5, Michael Boswell6, Veronica Ueckermann6, Susan Meiring1, Anne von Gottberg1,2, Cheryl Cohen1,7, Lynn Morris1,2, Jinal N. Bhiman1,2*, Penny L. Moore1,2*
Abstract
SARS-CoV-2 501Y.V2, a novel lineage of the coronavirus causing COVID-19, contains multiple mutations within two immunodominant domains of the spike protein. Here we show that this lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies. Furthermore 501Y.V2 shows substantialor complete escape from neutralizing antibodies in COVID-19 convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and may foreshadow reduced efficacy of current spike-based vaccines...
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer1, Frances Ayres1, Tandile Hermanus1, Mashudu Madzivhandila1, Prudence Kgagudi1, Bronwen E. Lambson1,2, Marion Vermeulen3, Karin van denBerg3,4, Theresa Rossouw5, Michael Boswell6, Veronica Ueckermann6, Susan Meiring1, Anne von Gottberg1,2, Cheryl Cohen1,7, Lynn Morris1,2, Jinal N. Bhiman1,2*, Penny L. Moore1,2*
Abstract
SARS-CoV-2 501Y.V2, a novel lineage of the coronavirus causing COVID-19, contains multiple mutations within two immunodominant domains of the spike protein. Here we show that this lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies. Furthermore 501Y.V2 shows substantialor complete escape from neutralizing antibodies in COVID-19 convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and may foreshadow reduced efficacy of current spike-based vaccines...